BioPharm International
April 01, 2006
Featured Article
19
4
The type of reactive moiety controls the site and stability of the covalent link and also the total number of PEGylation sites on a given protein.
April 01, 2006
Columns and Departments
19
4
RFID is currently the most advanced tracking technology, but manufacturers need to pursue a multilayered approach . . .
April 01, 2006
Columns and Departments
19
4
Coming from Wall Street. I'm often asked what "professional" investors think about the life sciences industry.
April 01, 2006
Columns and Departments
19
4
Interestingly, it is companies that already have the most capacity available to them that are building even more.
April 01, 2006
Columns and Departments
19
4
In recent years, FDA has made positive moves to foster innovation by streamling regulation. But the agency's recent proposal to exempt manufacturing for phase 1 clinical trials from GMP requirements seems ill advised.
April 01, 2006
Articles
19
4
Of all the protein products on the US market, at most 75 are likely to become genericized.
April 01, 2006
Articles
19
4
In the pharmaceutical industry, ultrafiltration (UF) membranes are used extensively in the downstream purification of recombinant proteins or monoclonal antibodies. However, the fouling of membranes after a unit operation?especially when recombinant proteins or monoclonal antibodies are highly concentrated?is a common problem. Typically, normalized water permeability (NWP) of a membrane can be reduced to about 20 percent of its original permeability at the end of an ultrafiltration-diafiltration (UF-DF) operation.
April 01, 2006
Columns and Departments
19
4
On January 17, 2006, the FDA released new regulations, effective June 1, 2006, which affect the production of most investigational drug and biologic products intended for phase 1 clinical trials. These regulations are much broader in scope than the Exploratory IND guidance released on the same day, and which apply only to low-risk, CDER-regulated clinical studies.